

Andrew D Zelenetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7852736/publications.pdf>

Version: 2024-02-01

234
papers

25,751
citations

12303

69
h-index

6818

155
g-index

237
all docs

237
docs citations

237
times ranked

19800
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016, 127, 2375-2390.	0.6	5,965
2	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 997-1007.	13.9	1,535
3	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	13.9	1,443
4	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	0.6	829
5	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , 2014, 123, 837-842.	0.6	693
6	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	0.8	610
7	Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 676-684.	0.8	562
8	Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2001, 19, 3918-3928.	0.8	555
9	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
10	A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. <i>Blood</i> , 2001, 97, 616-623.	0.6	402
11	Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2006, 24, 166-173.	0.8	382
12	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382
13	Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2004, 103, 3684-3688.	0.6	365
14	Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 1316-1323.	0.8	337
15	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1896-1903.	0.8	293
16	Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3776-3785.	0.8	289
17	Management of adverse events associated with idelalisib treatment: expert panel opinion. <i>Leukemia and Lymphoma</i> , 2015, 56, 2779-2786.	0.6	268
18	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	0.8	266

#	ARTICLE	IF	CITATIONS
19	Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1202-1208.	0.8	263
20	Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. <i>Blood</i> , 2004, 104, 3483-3489.	0.6	258
21	Normalization of pre-ASCT, FDG-PET imaging with second-line, non-“cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 1665-1670.	0.6	258
22	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	0.6	248
23	Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 106-111.	0.2	246
24	Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 102, 1989-1996.	0.6	235
25	Non-Hodgkin’s Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 288-334.	2.3	233
26	Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2010, 116, 4934-4937.	0.6	228
27	Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s Lymphomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 7565-7573.	0.8	226
28	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	5.1	219
29	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016, 128, 1112-1120.	0.6	177
30	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1391-1402.	0.8	177
31	Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 456-460.	0.8	175
32	Phase II-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2009, 27, 4357-4364.	0.8	163
33	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 484-560.	2.3	161
34	Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. <i>Cancer</i> , 2003, 98, 1196-1205.	2.0	154
35	Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3368-3375.	0.8	154
36	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. <i>Haematologica</i> , 2012, 97, 758-765.	1.7	153

#	ARTICLE	IF	CITATIONS
37	Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131 tositumomab. <i>Blood</i> , 2005, 105, 4576-4582.	0.6	152
38	Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, 1575-1581.	0.8	146
39	Non-Hodgkin's Lymphomas, Version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1282-1303.	2.3	144
40	Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 2004, 124, 645-652.	1.2	142
41	Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 158-163.	1.2	134
42	Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999. <i>British Journal of Haematology</i> , 2005, 130, 691-699.	1.2	123
43	Overview of Lymphoma Diagnosis and Management. <i>Radiologic Clinics of North America</i> , 2008, 46, 175-198.	0.9	116
44	NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 650-661.	2.3	116
45	Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2006, 134, 202-207.	1.2	111
46	Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2015, 125, 2579-2581.	0.6	111
47	Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 2196-2203.	0.6	111
48	High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. <i>Blood</i> , 2000, 96, 2399-2404.	0.6	108
49	Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression. <i>Leukemia and Lymphoma</i> , 2003, 44, 1027-1035.	0.6	107
50	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	2.3	107
51	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
52	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019, 133, 1964-1976.	0.6	104
53	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. <i>Journal of Experimental Medicine</i> , 2011, 208, 1799-1807.	4.2	103
54	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	0.8	97

#	ARTICLE	IF	CITATIONS
55	Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. <i>Blood</i> , 2004, 103, 1862-1868.	0.6	96
56	High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. <i>British Journal of Haematology</i> , 2010, 148, 890-897.	1.2	90
57	Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. <i>Blood</i> , 2012, 119, 2093-2099.	0.6	88
58	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <i>Blood</i> , 2019, 133, 137-146.	0.6	88
59	Pralatrexate, a novel class of antifolate with high affinity for the reduced folate carrier type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. <i>British Journal of Haematology</i> , 2007, 139, 425-428.	1.2	85
60	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	2.8	81
61	Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 3047-3049.	3.3	81
62	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	3.2	80
63	Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. <i>Blood</i> , 2006, 107, 2477-2485.	0.6	79
64	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 600-609.	0.6	79
65	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016, 128, 469-469.	0.6	79
66	Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era. <i>Cancer</i> , 2012, 118, 2944-2951.	2.0	78
67	Diffuse Large B-Cell Lymphoma Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 196-231.	2.3	76
68	Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network. <i>Journal of Clinical Oncology</i> , 2008, 26, 5107-5112.	0.8	75
69	Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. <i>British Journal of Haematology</i> , 2009, 145, 34-39.	1.2	72
70	Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. <i>Blood</i> , 2005, 106, 3383-3385.	0.6	71
71	Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-Cell Lymphoma: A Single Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 8-14.	0.2	71
72	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. <i>Cancer</i> , 2016, 122, 559-564.	2.0	67

#	ARTICLE	IF	CITATIONS
73	Marker-controlled watershed for lymphoma segmentation in sequential CT images. <i>Medical Physics</i> , 2006, 33, 2452-2460.	1.6	66
74	Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses. <i>Journal of Clinical Oncology</i> , 2009, 27, 491-497.	0.8	66
75	Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. <i>British Journal of Haematology</i> , 2013, 163, 487-495.	1.2	64
76	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	0.6	62
77	Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab. <i>Cancer</i> , 2013, 119, 3662-3671.	2.0	61
78	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1458-1464.	0.6	61
79	Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIGÂ®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. <i>Blood</i> , 2014, 124, 330-330.	0.6	61
80	¹⁸ F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2163-2167.	0.6	60
81	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
82	Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2004-2009.	2.0	52
83	Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. <i>British Journal of Haematology</i> , 2019, 184, 660-663.	1.2	51
84	Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity. <i>Journal of Clinical Oncology</i> , 2008, 26, 1858-1864.	0.8	50
85	Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. <i>British Journal of Haematology</i> , 2015, 170, 85-95.	1.2	50
86	MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. <i>Blood</i> , 2000, 95, 2930-2936.	0.6	49
87	Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. <i>Cancer</i> , 2007, 110, 2528-2534.	2.0	49
88	A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. <i>Blood</i> , 2018, 131, 1805-1808.	0.6	49
89	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. <i>Lancet Haematology</i> , 2019, 6, e366-e374.	2.2	49
90	Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. <i>Blood</i> , 2002, 99, 2554-2561.	0.6	48

#	ARTICLE	IF	CITATIONS
91	Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 318-328.	1.5	48
92	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e879-e890.	2.2	48
93	Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 652-655.	1.2	47
94	Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes. <i>Clinical Cancer Research</i> , 2010, 16, 719-726.	3.2	46
95	Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. <i>British Journal of Haematology</i> , 2017, 176, 591-599.	1.2	46
96	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	0.6	46
97	R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy. <i>Leukemia and Lymphoma</i> , 2005, 46, 541-547.	0.6	43
98	Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. <i>Haematologica</i> , 2016, 101, 1237-1243.	1.7	42
99	Prospective Study of ¹⁸ F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 728-734.	2.8	41
100	Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1538-1542.	2.0	38
101	High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. <i>Leukemia and Lymphoma</i> , 2012, 53, 1113-1116.	0.6	38
102	Non-Hodgkin's Lymphomas, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 916-946.	2.3	38
103	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	0.6	38
104	Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. <i>Oncogene</i> , 2001, 20, 7686-7693.	2.6	37
105	Non-Hodgkin's Lymphoma Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 258.	2.3	37
106	Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. <i>Cancer</i> , 2014, 120, 1993-1999.	2.0	36
107	A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B-Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 354-360.	2.0	35
108	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	2.8	35

#	ARTICLE	IF	CITATIONS
109	Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. <i>Leukemia and Lymphoma</i> , 2011, 52, 1188-1199.	0.6	33
110	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	0.8	32
111	Hepatitis B virus management to prevent reactivation after chemotherapy: a review. <i>Supportive Care in Cancer</i> , 2012, 20, 2999-3008.	1.0	31
112	Phase II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2015, 168, 663-670.	1.2	31
113	Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2015, 171, 776-783.	1.2	30
114	Non-Hodgkin's Lymphomas, Version 3.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1487-1498.	2.3	29
115	FDG-PET Lymphoma Demonstration Project Invitational Workshop. <i>Academic Radiology</i> , 2007, 14, 330-339.	1.3	27
116	Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2011, 17, 2493-2501.	3.2	27
117	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	2.5	26
118	Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. <i>Blood</i> , 2001, 97, 1929-1936.	0.6	25
119	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	2.8	25
120	Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL. <i>Blood</i> , 2006, 108, 532-532.	0.6	25
121	Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. <i>Radiology</i> , 2015, 277, 518-526.	3.6	23
122	A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma. <i>Genes Chromosomes and Cancer</i> , 1993, 6, 140-150.	1.5	22
123	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. <i>American Journal of Hematology</i> , 2016, 91, 770-775.	2.0	22
124	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	2.5	22
125	Guidelines for NHL: Updates to the Management of Diffuse Large B-Cell Lymphoma and New Guidelines for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders and T-Cell Large Granular Lymphocytic Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 797-800.	2.3	21
126	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	1.3	21

#	ARTICLE	IF	CITATIONS
127	A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients \geq 65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2014, 124, 1986-1986.	0.6	21
128	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2991-2991.	0.6	21
129	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019, 60, 894-903.	0.6	18
130	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	3.2	17
131	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, e163-e166.	1.7	17
132	Involved-site radiotherapy for <i>Helicobacter pylori</i> -independent gastric MALT lymphoma: 26 years of experience with 178 patients. <i>Blood Advances</i> , 2021, 5, 1830-1836.	2.5	17
133	Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. <i>American Journal of Hematology</i> , 2021, 96, 1211-1222.	2.0	16
134	Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. <i>Blood Advances</i> , 2021, 5, 2879-2889.	2.5	16
135	Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. <i>Blood</i> , 2015, 126, LBA-5-LBA-5.	0.6	16
136	Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Detected by Clonotypic Polymerase Chain Reaction Despite Continuous Pathologic Remission Induced by Involved-Field Radiotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3768-3772.	0.8	15
137	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. <i>Bone Marrow Transplantation</i> , 2015, 50, 1293-1298.	1.3	15
138	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. <i>Blood Advances</i> , 2021, 5, 4185-4197.	2.5	15
139	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	3.2	13
140	Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation. <i>Journal of Oncology Practice</i> , 2011, 7, 213-218.	2.5	12
141	Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. <i>Leukemia and Lymphoma</i> , 2013, 54, 2155-2162.	0.6	12
142	The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of \geq 12 months. <i>British Journal of Haematology</i> , 2016, 173, 260-264.	1.2	12
143	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. <i>Leukemia and Lymphoma</i> , 2019, 60, 1438-1446.	0.6	12
144	The Importance of Molecular Phenotype in Predicting Overall Survival in Patients with Relapsed or Primary Refractory DLBCL Treated with Second-Line Chemotherapy and ASCT. <i>Blood</i> , 2004, 104, 10-10.	0.6	12

#	ARTICLE	IF	CITATIONS
145	Surveillance Imaging for Lymphoma: Pros and Cons. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e388-e395.	1.8	11
146	Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2010, 116, 1793-1793.	0.6	11
147	Automated matching and segmentation of lymphoma on serial CT examinations. Medical Physics, 2006, 34, 55-62.	1.6	10
148	Multidimensional Single-Cell Analysis of BCR Signaling Reveals Proximal Activation Defect As a Hallmark of Chronic Lymphocytic Leukemia B Cells. PLoS ONE, 2014, 9, e79987.	1.1	10
149	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. Blood, 2019, 134, 1619-1619.	0.6	9
150	[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leukemia and Lymphoma, 2017, 58, 809-815.	0.6	8
151	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood, 2022, 140, 1822-1826.	0.6	8
152	A novel gene STORP (STOMatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22. European Journal of Haematology, 2000, 64, 104-113.	1.1	7
153	MUC-1 Mucin Protein Expression in B-cell Lymphomas. Applied Immunohistochemistry and Molecular Morphology, 2003, 11, 28-32.	0.6	7
154	Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma. British Journal of Haematology, 2014, 164, 646-652.	1.2	7
155	High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1274-1281.	2.3	7
156	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Advances, 2021, 5, 345-351.	2.5	7
157	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. Blood, 2019, 134, 22-22.	0.6	7
158	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. Blood, 2013, 122, 640-640.	0.6	7
159	Differential Expression Patterns of c-REL Protein in Classic and Nodular Lymphocyte Predominant Hodgkin Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2004, 12, 211-215.	0.6	6
160	Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica, 2022, 107, 1144-1152.	1.7	6
161	High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and CVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma. Blood, 2019, 134, 2837-2837.	0.6	6
162	Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience. Blood, 2011, 118, 2688-2688.	0.6	6

#	ARTICLE	IF	CITATIONS
163	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020, 136, 11-12.	0.6	6
164	Treatment Response of Cutaneous Mantle Cell Lymphoma to Ibrutinib and Radiotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e113-e115.	0.2	5
165	The Role of Biosimilars. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 626-629.	2.3	5
166	Chronic Lymphocytic Leukemia: Individualizing Treatment Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 713-715.	2.3	5
167	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 173.	1.0	5
168	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 17-18.	0.6	5
169	Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment. <i>Blood</i> , 2006, 108, 3057-3057.	0.6	5
170	Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma. <i>Blood</i> , 2007, 110, 603-603.	0.6	5
171	Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 510-510.	0.6	5
172	Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 749-756.e1.	0.2	4
173	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	0.6	4
174	ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 5244-5244.	0.6	4
175	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1555-1555.	0.6	4
176	Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980-1999. <i>Blood</i> , 2004, 104, 614-614.	0.6	4
177	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016, 128, 2955-2955.	0.6	4
178	Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma. <i>Oncology</i> , 2003, 17, 21-6.	0.4	4
179	Synchronous presentation of systemic and brain non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 2370-2373.	0.6	3
180	Emerging Treatment Options for B-Cell Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 666-669.	2.3	3

#	ARTICLE	IF	CITATIONS
181	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	0.6	3
182	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	0.6	3
183	Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform. <i>Blood</i> , 2013, 122, 1761-1761.	0.6	3
184	Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). <i>Blood</i> , 2016, 128, 1778-1778.	0.6	3
185	Outcome of Initial Observation in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 1803-1803.	0.6	3
186	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 654-654.	0.6	3
187	The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 701-707.	3.3	2
188	Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT). <i>Blood</i> , 2019, 134, 2826-2826.	0.6	2
189	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	0.6	2
190	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. <i>Blood</i> , 2012, 120, 1618-1618.	0.6	2
191	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. <i>Blood</i> , 2016, 128, 1777-1777.	0.6	2
192	Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2904-2904.	0.6	2
193	The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	0.6	2
194	Will radioimmunotherapy survive?. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 782-4.	0.3	2
195	Reply to A. Hättmann et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e490-e491.	0.8	1
196	International Adaptation and Use of NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 838-841.	2.3	1
197	Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2939-2946.	0.6	1
198	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2834-2834.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients. <i>Blood</i> , 2019, 134, 1758-1758.	0.6	1
200	Clinical Outcomes and Cost of Outpatient Community-Based Treatment for Rituximab Refractory Non-Hodgkins Lymphoma (NHL) Patients.. <i>Blood</i> , 2004, 104, 3132-3132.	0.6	1
201	PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 4245-4245.	0.6	1
202	The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2005, 106, 2072-2072.	0.6	1
203	Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.. <i>Blood</i> , 2012, 120, 2669-2669.	0.6	1
204	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 3655-3655.	0.6	1
205	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. <i>Blood</i> , 2019, 134, 2850-2850.	0.6	1
206	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2021, 138, 2447-2447.	0.6	1
207	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-38.	0.6	1
208	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
209	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	2.8	1
210	Reply to M.E. Juweid et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e721-e722.	0.8	0
211	Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy. <i>British Journal of Haematology</i> , 2020, 191, 326-328.	1.2	0
212	High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin's Lymphoma.. <i>Blood</i> , 2005, 106, 2073-2073.	0.6	0
213	Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival. <i>Blood</i> , 2007, 110, 1280-1280.	0.6	0
214	Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 1649-1649.	0.6	0
215	Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome. <i>Blood</i> , 2008, 112, 3759-3759.	0.6	0
216	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. <i>Journal of Cell Biology</i> , 2011, 194, i9-i9.	2.3	0

#	ARTICLE	IF	CITATIONS
217	An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.. Blood, 2012, 120, 2656-2656.	0.6	0
218	Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2012, 120, 792-792.	0.6	0
219	Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN. Blood, 2012, 120, 1610-1610.	0.6	0
220	Tumor Associated Macrophage Expression, CD163, Is Associated with Poorer Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1583-1583.	0.6	0
221	A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients. Blood, 2013, 122, 3058-3058.	0.6	0
222	Excellent Outcomes For Limited-Stage Diffuse Large B-Cell Lymphoma In The Rituximab Era: A Retrospective Analysis From Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 3030-3030.	0.6	0
223	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. Blood, 2015, 126, 2668-2668.	0.6	0
224	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. Blood, 2015, 126, 2691-2691.	0.6	0
225	Analysis of an Online Decision Support Tool for Chronic Lymphocytic Leukemia: Disparities in Treatment Selection Between Experts and Community Practitioners. Blood, 2016, 128, 5958-5958.	0.6	0
226	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. Blood, 2016, 128, 4119-4119.	0.6	0
227	Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma. Blood, 2016, 128, 4115-4115.	0.6	0
228	MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 294-294.	0.6	0
229	Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia. Blood, 2019, 134, 4724-4724.	0.6	0
230	Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment Selection. Blood, 2019, 134, 4299-4299.	0.6	0
231	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 2529-2529.	0.6	0
232	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. Blood, 2021, 138, 2513-2513.	0.6	0
233	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. Blood, 2021, 138, 4578-4578.	0.6	0
234	Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool. Blood, 2020, 136, 41-42.	0.6	0